Cargando…

Factors associated with fatal coronavirus disease 2019 infections among cancer patients in the US FDA Adverse Event Reporting System database

AIM: To explore factors affecting coronavirus disease 2019 (COVID-19) mortality among cancer patients based on a pharmacovigilance database. METHODS: US FDA Adverse Event Reporting System (FAERS) quarterly data extract files were reviewed for quarters two, three and four of 2020 (i.e., April to Dece...

Descripción completa

Detalles Bibliográficos
Autor principal:	Abdel-Rahman, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582593/ https://www.ncbi.nlm.nih.gov/pubmed/34726930 http://dx.doi.org/10.2217/fon-2021-0816

Ejemplares similares

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
por: Sanagawa, Akimasa, et al.
Publicado: (2018)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age
por: ABE, Junko, et al.
Publicado: (2015)

Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
por: Picaut, Philippe
Publicado: (2018)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database
por: Lehrer, Steven, et al.
Publicado: (2018)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
por: Kavanagh, Kevin T, et al.
Publicado: (2019)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
por: Wang, Wei, et al.
Publicado: (2023)

Influence of anticancer agents on sexual function: An in vivo study based on the US FDA Adverse Event Reporting System
por: Kataoka, Tomoya, et al.
Publicado: (2021)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Analysis of reported adverse events of pipeline stents for intracranial aneurysms using the FDA MAUDE database
por: Porwal, Mokshal H., et al.
Publicado: (2023)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database
por: Guo, Mingxing, et al.
Publicado: (2022)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
por: Zhou, Shuang, et al.
Publicado: (2022)

Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
por: Li, Hailong, et al.
Publicado: (2023)

Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system
por: Taher, Mohamed Kadry, et al.
Publicado: (2021)

Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
por: Kong, Qingli, et al.
Publicado: (2023)

1783. Acute Kidney Injury Associations with Antibiotics: A Pharmacovigilance Study of the US FDA Adverse Event Reporting System
por: Kochuparambil, Jose J, et al.
Publicado: (2023)

A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use
por: Shen, Juan, et al.
Publicado: (2019)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Adverse Events in Total Ankle Arthroplasty, Analysis of the FDA Medical and User Facility Device Experience Database
por: Mahmoud, Karim, et al.
Publicado: (2019)

Pneumothorax as an Adverse Drug Event: An Exploratory Aggregate Analysis of the US FDA AERS Database Including a Confounding by Indication Analysis Inspired by Cornfield's Condition
por: Hauben, Manfred, et al.
Publicado: (2013)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ti87qknja8kei09lu7ivik16i